Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia

Psychiatry Research

Volumn 141, Issue 2, 2006, Pages 123-128

  Shinkai, Takahiro ^a,b,f   Müller, Daniel J ^a,e   De Luca, Vincenzo ^a   Shaikh, Sajid ^a   Matsumoto, Chima ^b   Hwang, Rudi ^a   King, Nicole ^a   Trakalo, Joseph ^a   Potapova, Natalia ^a   Zai, Gwyneth ^a   Hori, Hiroko ^b   Ohmori, Osamu ^b,d   Meltzer, Herbert Y ^c   Nakamura, Jun ^b   Kennedy, James L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Wakato Hospital   (Japan)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Free radical; Genetics; Glutathione peroxidase; Oxidative stress; Polymorphism; Schizophrenia; Tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; GLUTATHIONE PEROXIDASE 1; LEUCINE; NEUROLEPTIC AGENT; PROLINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; DIPEPTIDES; DYSKINESIA, DRUG-INDUCED; FEMALE; FREE RADICALS; GENOTYPE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; POLYMORPHISM, GENETIC; REACTIVE OXYGEN SPECIES; SCHIZOPHRENIA;

EID: 33645035694     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2004.06.023     Document Type: Article

References (41)

1. O.A. Andreassen, and H.A. Jorgensen Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Progress in Neurobiology 61 2000 525 541
2. V.S. Basile, M. Masellis, F. Badri, A.D. Paterson, H.Y. Meltzer, J.A. Lieberman, S.G. Potkin, F. Macciardi, and J.L. Kennedy Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia Neuropsychopharmacology 21 1999 17 27
3. V.S. Basile, V. Özdemir, M. Masellis, M.L. Walker, H.Y. Meltzer, J.A. Lieberman, S.G. Potkin, G. Alva, W. Kalow, F.M. Macciardi, and J.L. Kennedy A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia Molecular Psychiatry 5 2000 410 417
4. L. Bischot, G. Van den Brink, and A.J. Porsius Vitamin E in extrapyramidal disorders Pharmacy World and Science 15 1993 146 150
5. D.A. Butterfield, A. Castegna, J. Drake, G. Scapagnini, and V. Calabrese Vitamin E and neurodegenerative disorders associated with oxidative stress Nutritional Neuroscience 5 2002 229 239
6. D.E. Casey, J. Gerlach, G. Magelund, and T.R. Christensen Gamma-acetylenic GABA in tardive dyskinesia Archives of General Psychiatry 37 1980 1376 1379
7. J.B. de Haan, C. Bladier, P. Griffiths, M. Kelner, R.D. O'Shea, N.S. Cheung, R.T. Bronson, M.J. Silvestro, S. Wild, S.S. Zheng, P.M. Beart, P.J. Hertzog, and I. Kola Mice with a homozygous null mutation for the most abundant glutathione peroxidase, Gpx1, show increased susceptibility to the oxidative stress-inducing agents paraquat and hydrogen peroxide Journal of Biological Chemistry 273 1998 22528 22536
8. L. Forsberg, U. de Faire, and R. Morgenstern Low yield of polymorphisms from EST blast searching: analysis of genes related to oxidative stress and verification of the P197L polymorphism in GPX1 Human Mutation 13 1999 294 300
9. L. Forsberg, U. de Faire, S.L. Marklund, P.M. Andersson, B. Stegmayr, and R. Morgenstern Phenotype determination of a common Pro-Leu polymorphism in human glutathione peroxidase 1 Blood Cells, Molecules & Diseases 26 2000 423 426
10. Guy, W., 1976. Abnormal involuntary movement scale (AIMS). ECDEU Assessment Manual for Psychopharmacology, revised. Department Health, Education, and Welfare, Washington, DC, US DWEW publication, pp. 534-537.
11. H. Hori, O. Ohmori, T. Shinkai, H. Kojima, C. Okano, T. Suzuki, and J. Nakamura Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia Neuropsychopharmacology 23 2000 170 177
12. Y.J. Hu, and A.M. Diamond Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium Cancer Research 63 2003 3347 3351
13. K. Ishida, T. Morino, K. Takagi, and Y. Sukenaga Nucleotide sequence of a human gene for glutathione peroxidase Nucleic Acids Research 15 1987 10051
14. D.V. Jeste, and J.R. Kelsoe Schizophrenia, tardive dyskinesia, and a D3 receptor gene variant: a new twist on dyskinesias? Molecular Psychiatry 2 1997 86 88
15. J. Kane, G. Honigfeld, J. Singer, and H. Meltzer Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Archives of General Psychiatry 45 1988 789 796
16. T. Kapitany, K. Meszaros, E. Lenzinger, S.D. Schindler, C. Barnas, K. Fuchs, W. Sieghart, H.N. Aschauer, and S. Kasper Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia Schizophrenia Research 32 1998 101 106
17. C. Kiss, J. Li, A. Szeles, R.Z. Gizatullin, V.I. Kashuba, T. Lushnikova, A.I. Protopopov, M. Kelve, H. Kiss, I.D. Kholodnyuk, S. Imreh, G. Klein, and E.R. Zabarovsky Assignment of the ARHA and GPX1 genes to human chromosome bands 3p21.3 by in situ hybridization and with somatic cell hybrids Cytogenetics and Cell Genetics 79 1997 228 230
18. D.K. Lahiri, and J.I. Nurnberger Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies Nucleic Acids Research 19 1991 5444
19. P.R. Latimer Tardive dyskinesia: a review Canadian Journal of Psychiatry 40 Suppl 2 1995 S49 S54
20. B. Lerer, R.H. Segman, H. Fangerau, A.K. Daly, V.S. Basile, R. Cavallaro, H.N. Aschauer, R.G. McCreadie, S. Ohlraun, N. Ferrier, M. Masellis, M. Verga, J. Scharfetter, M. Rietschel, R. Lovlie, U.H. Levy, H.Y. Meltzer, J.L. Kennedy, V.M. Steen, and F. Macciardi Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism Neuropsychopharmacology 27 2002 105 119
21. J.B. Lohr, R. Kuczenski, H.S. Bracha, M. Moir, and D.V. Jeste Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia Biological Psychiatry 28 1990 535 539
22. M. Masellis, V. Basile, H.Y. Meltzer, J.A. Lieberman, S. Sevy, F.M. Macciardi, P. Cola, A. Howard, F. Badri, M.M. Nothen, W. Kalow, and J.L. Kennedy Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients Neuropsychopharmacology 19 1998 123 132
23. H.Y. Meltzer An overview of the mechanism of action of clozapine Journal of Clinical Psychiatry 55 Suppl B 1994 47 52
24. C.H. Miller, I. Simioni, H. Oberbauer, J. Schwitzer, C. Barnas, F. Kulhanek, K.E. Boissel, U. Meise, H. Hinterhuber, and W.W. Fleischhacker Tardive dyskinesia prevalence rates during a ten-year follow-up Journal of Nervous and Mental Disease 183 1995 404 407
25. H. Morgenstern, and W.M. Glazer Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study Archives of General Psychiatry 50 1993 723 733
26. D.J. Müller, T. Shinkai, V. De Luca, and J.L. Kennedy Clinical implications of pharmacogenomics for tardive dyskinesia The Pharmacogenomics Journal 4 2004 77 87
27. P.S. Naidu, A. Singh, and S.K. Kulkarni Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms British Journal of Clinical Pharmacology 136 2002 193 200
28. P.S. Naidu, A. Singh, and S.K. Kulkarni Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia Neuropharmacology 44 2003 1100 1106
29. O. Ohmori, T. Suzuki, H. Kojima, T. Shinkai, T. Terao, T. Mita, and K. Abe Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genetype in Japanese schizophrenics Schizophrenia Research 32 1998 107 113
30. O. Ohmori, T. Shinkai, H. Hori, C. Matsumoto, and J. Nakamura A perspective on molecular genetic studies of tardive dyskinesia: one clue for individualized antipsychotic drug therapy Progress in Neuro-psychopharmacology & Biological Psychiatry 27 2003 581 586
31. N.R. Schooler, and J.M. Kane Research diagnoses for tardive dyskinesia Archives of General Psychiatry 39 1982 486 487
32. R.E. See Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride Neuroscience Letters 129 1991 265 268
33. gly alleles to susceptibility Psychopharmacology 152 2000 408 413
34. R.H. Segman, U. Heresco-Levy, B. Finkel, T. Goltser, R. Shalem, M. Schlafman, A. Dorevitch, A. Yakir, D. Greenberg, A. Lerner, and B. Lerer Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia Molecular Psychiatry 6 2001 225 229
35. P.C. Sham, and D. Curtis Monte Carlo tests for associations between disease and alleles at highly polymorphic loci Annals of Human Genetics 59 1995 97 105
36. V.M. Steen, R. Løvlie, T. MacEwan, and R.G. McCreadie Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients Molecular Psychiatry 2 1997 139 145
37. D. Tarsy, and R.J. Baldessarini The pathophysiologic basis of tardive dyskinesia Biological Psychiatry 12 1977 431 450
38. G. Tsai, D.C. Goff, R.W. Chang, J. Flood, L. Baer, and J.T. Coyle Markers of glutamatergic neurotransmission and oxidative stress associated tardive dyskinesia American Journal of Forensic Psychiatry 155 1998 1207 1213
39. F. Ursini, M. Maiorino, and C. Gregolin The selenoenzyme phospholipid hydroperoxide glutathione peroxidase Biochimica et Biophysica Acta 839 1985 62 70
40. J.K. Yao, R.D. Reddy, and D.P. van Kammen Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications CNS Drugs 15 2001 287 310
41. Z. Zhang, X. Zhang, G. Hou, W. Sha, and G.P. Reynolds The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism Journal of Psychiatric Research 36 2002 317 324